Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What’s the message board sentiment on the change of events. I feel like Peter stepping down is a good thing as well.
When does VSBLTY report q4 2021?
Why the move this afternoon?
I’m not sure this can run or the merger can go thru until the lawsuit is settled. At this point I’m not sure what’s holding up the merger besides that.
I believe we need to stay above $3 to get this merger to go thru. There’s a party involved that doesn’t want they to happen.
Sounds like any doubt of the merger can be put to bed. Unless ANY can get back above $4 a reverse stock split is coming?
New Zealand could very well be where they launch in early 2022.
How about getting on the NASDAQ? That’s important to take this to the next level. Sounds like FDA approval by end of 2021. New business venture finally being introduced end of the month. Cannabis business will start generating revenue in q4.
Seems to be very well received and market sentiment is it’s positive m. The “in the know” wouldn’t put that much up without thinking there was a high probability that approval was near. I have to admit I wasn’t overly excited by seeing additional shares issued, but was nervous about cash on hand.
Good volume coming thru. Possible FDA update?
Long time counsel Thomas James resigns for personal reasons. First, Henry, then Fleet and now James. Odd that all would be leaving if XXII had such a bright future.
From what I can recall. It was Magic 0 that was released in Spain for maybe a few months before the company pulled them back due to taste. I guess European cigarettes taste different than American cigarettes. Then we were about to relaunch them with a new proprietary filter, but that never happened because a ruling was passed that Tobacco companies couldn’t have any information on a cigarette pack. Before that tobacco company could put the nicotine content on the pack which was a main reason the company decided to launch there to begin with. Once it went to a plain pack xxii decided it would be near impossible to market our cigarettes.
2 million shares traded after hours, someone putting some bets in place.
Just yearly bonuses being distributed.
FDA commissioner resigns. Jeez
I’ve been around for quite a few conference calls and they’ve been mostly business as usual. It’s not Henry's MO to throw out a surprise, although I wish he would. When XXII has something to tell they usually issue a press release ASAP. I’m looking for increased revenues from manufacturing and an update on MRTP which will probably be submitted on Dec 31st like it was last time.
Nice recovery!
Wouldn’t be surprised to see a run leading up to the FDAs Tobacco and Nicotine Product Regulation and Policy Conference on Oct 25th.
Wonder if our situation is complicated since we don’t own the cannibas patents but have the rights to license. If we were bought would the rights be transferable?
That’s a big jump from $3-$4 they were last estimating. Although they haven’t come close to getting it right hopefully we start another run north soon.
I’m a shareholder of Altria and we received our annual proxy card to vote. An interesting proposal to reduce and disclose nicotine levels in Cigarette Brands was added. It’s worth noting the board of directors recommended a vote against this proposal.
Was he heading our fda application? Might explain the recent drop in pps.
Here the company’s timeline for Modified Risk Application.
The Performance Vesting Options will vest as follows: (i) one hundred thousand (100,000) will vest if and when Dr. Swauger is successful in submitting a complete Modified Risk Tobacco Product (“MRTP”) application to the Center for Tobacco Products (“CTP”) of the U.S. Food and Drug Administration (“FDA”) for the Company’s Very Low Nicotine MRTP candidate known as “BRAND A” on or before March 31, 2019, (ii) one hundred thousand (100,000) will vest if and when the submitted MRTP application is submitted by the CTP to the FDA’s Tobacco Products Scientific Advisory Committee (“TPSAC”) for review, and (iii) the remaining one hundred thousand (100,000) will vest if and when Dr. Swauger is successful in securing a Modified Risk Tobacco Product (“MRTP”) authorization from the FDA on or before December 31, 2020 or before the termination of his employment, whichever is earlier (provided that the date December 31, 2020 will be modified in a corresponding fashion by any decision to extend the required submission date of the MRTP application to the FDA).
How about a deal with China National Tobacco for Technology and MSA to get in the US market?
What would happen to the stock price if we have no BAT deal and Henry did another capital raise come Oct 1st? I know we have plenty of money on hand, but Henry could raise a substantial amount of money with the current stock price. It's a possible scenario that we've seen before and curious of others opinion.
Agree, but do we still end in the green?
Honestly I wouldn't be surprised to see no deal until BAT gets all the information from FDA and sees what happens with XXII Modified Risk Application. These bigs companies would rather pay more for something when they have all the info. Although moving forward with the deal is a drop in the bucket at 7 million and they could just sit on it which wouldn't deliver us any revenue. IMO. I'll be selling a few shares @ $3 and riding the rest until the payday if and when that comes.
Two large blocks at $2.29 to close
Someone just made some large buys 300k
So we broke the trend in a positive direction?
Read this article on the BAT board news feed.
FDA Seeks to Reduce Nicotine in Cigarettes to Nonaddictive Levels -- 5th Update
Source: Dow Jones News
By Jennifer Maloney
U.S. health officials said Friday they want tobacco companies to make all cigarettes with such low levels of nicotine that they are no longer addictive, part of a sweeping regulatory overhaul that threatens Big Tobacco's main moneymaker.
The Food and Drug Administration also said it would encourage smokers to switch to products such as e-cigarettes and smokeless tobacco that are less dangerous than cigarettes. The so-called harm-reduction strategy is a break by the U.S. government from an abstinence-only approach to fighting tobacco-related diseases and deaths.
Shares of major tobacco companies, which have been reaping growing profits in the U.S. market even as the number of smokers dwindles, tumbled Friday on the surprise move. Marlboro maker Altria Group Inc. fell 10%, while British American Tobacco PLC, maker of Camel cigarettes, dropped 8.5%, erasing tens of billions of market value.
"The problem isn't just nicotine, the problem is the delivery mechanism, " FDA Commissioner Scott Gottlieb said at a press conference Friday.
"Cigarettes will likely remain incredibly toxic.... We may be able to reach a day when the most harmful products will no longer be capable of addicting our children," he said.
Dr. Gottlieb said the FDA's new approach would consider "a continuum of risk for nicotine delivery," from combustible products such as cigarettes to replacement therapies like nicotine gums. Nicotine hooks people on cigarettes, but nicotine itself doesn't cause cancer, heart disease or lung disease, he noted. It is other harmful compounds in cigarette smoke that kill 480,000 people in the U.S. each year, according to the Centers for Disease Control and Prevention.
In addition to pursuing regulation to "render cigarettes minimally addictive," Dr. Gottlieb said the FDA would consider a ban on menthol cigarettes.
The announcement is the biggest step by the U.S. government to curb smoking since a landmark legal settlement in 1998. In addition to paying more than $100 billion to help states pay for health care, tobacco companies agreed to restrictions on the use of cartoons in marketing, as well as transit advertising, billboards and free product samples.
"This is a huge switch from the 'tobacco-free world'. approach to tobacco and nicotine by U.S. government agencies," said David Sweanor, a Canadian law professor and tobacco expert who supports the harm-reduction approach.
The FDA began regulating the industry in 2009 but that move in some ways proved beneficial to Big Tobacco by grandfathering in cigarettes already on the market and eliminating regulatory uncertainty. The FDA's new stance "represents a paradigm shift in regulatory risk for U.S. tobacco companies," Stifel analyst Christopher Growe told clients in a note Friday.
Altria, which supported the 2009 legislation that gave the FDA authority to reduce nicotine levels, said "any proposed rule such as a nicotine product standard must be based on science and evidence, must not lead to unintended consequences and must be technically achievable."
BAT's U.S. subsidiary Reynolds American, which also sells nicotine gum, e-cigarettes and smokeless tobacco, said: "We are well prepared and look forward to participating in a thorough process to develop a comprehensive plan for tobacco and nicotine regulation."
Imperial Brands PLC, which sells the Winston and Kool brands, said "it's too early to understand the practical implications" of the FDA's new position. Philip Morris International Inc., which doesn't sell products in the U.S. but has applications pending before the FDA, didn't respond to a request for comment.
Some tobacco analysts were skeptical, saying such regulation would take years to develop and would likely be litigated. Others questioned the public-health benefit, suggesting smokers would just smoke more cigarettes to compensate for the lower levels of nicotine.
Citigroup analyst Adam Spielman said he doesn't believe the FDA will be able to lower nicotine to nonaddictive levels because defining that level would be difficult and there would be political opposition. "We don't believe the proposal to reduce nicotine in cigarettes dramatically is practical," Mr. Spielman said.
Nicotine levels in cigarettes can be reduced in different ways. Manufacturers can adjust the blend of tobacco leaves or use different types of paper or filters. Nicotine can also be stripped from the leaf in the manufacturing process.
But products with very low levels of nicotine have never garnered a significant share of the U.S. market. In 1989, Philip Morris Cos., the company now known as Altria, introduced an ultralow-nicotine cigarette called Next De-Nic, created through a process that stripped the majority of the nicotine from the tobacco leaf similar to the way caffeine is removed from coffee beans.
The FDA also said Friday it will allow more time for makers of e-cigarettes and vaping products to submit products for agency review. Those that were on the market in August 2016 won't be subject to review until 2021 or 2022.
The FDA's shift comes as the agency considers whether to approve new health-related marketing claims for several cigarette alternatives. In April, Reynolds American submitted applications to market six styles of Camel Snus tobacco pouches as being less harmful than cigarettes. Philip Morris International also has a health-claim application pending for a new device that heats tobacco instead of burning it. Analysts said the FDA's new position could bode well for such products.
Saabira Chaudhuri contributed to this article
Write to Jennifer Maloney at jennifer.maloney@wsj.com
(END) Dow Jones Newswires
July 28, 2017 17:26 ET (21:26 GMT)
Another question is what is typically the percentage of overall crop that gets destroyed?
I think the time that is wasted is the biggest expense.
Thanks for clarifying. I figured it wasn't anything earth shattering as the SP didn't move.
BREAKING DOWN 'Confidential Treatment Order - CTO'
Companies would typically seek a CTO in order to keep information that would otherwise put it at a disadvantage, a secret. For example, a company may apply for such an order to keep information regarding a pricing arrangement made with a partner, secret, since competitors finding out this information may go after the partner with a more competitive price.
Read more: Confidential Treatment Order - CTO Definition | Investopedia http://www.investopedia.com/terms/c/confidential-treatment-order.asp#ixzz4c4JajVuJ
Follow us: Investopedia on Facebook
Did today's news give any additional info that we didn't already know?
It's probably a long shot but now that we have dark cloud(lawsuit) cleared up maybe we hear about a partnership or deal. I have to imagine that a company doesn't want to do business with someone in a legal battle. Here's to hoping....
I wonder if today movement was from a verdict/decision they received. I remember from Karin's post that the some court date got moved to today. I can't find her post, looks like it might have been deleted for some reason.
This has been trading sideways since the pull back of the FDA news. We're in for a .10 fall with any negative news(declining revenues). Today's news was released to hopefully prop us up a little while longer.
I'd be shocked if we do hit considering we pulled back on Magic and Redsun is basically promoting itself. I don't see any other revenue drivers at the moment. We're contingent on a partnership and FDA approval. Like it long term for the latter reason but your probably on point with the prediction.